Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Montelukast on Allergic Rhinitis
NCT05381207Phase 1Unknown
- Sponsor
- Assiut University
- Start
- Oct 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of montelukast in allergic rhinitis (AR) (2 arms), sponsored by Assiut University. Primary endpoints: Nasal symptoms at 3 months, Laboratory findings at 3 months and 1 more. Status: unknown.
02
Drugs
montelukast
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT05381207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05381207.